Methotrexate Alternatives: Are There Other DMARD Options?

Methotrexate has been the cornerstone of rheumatoid arthritis treatment since the 1980s, but it is far from the only disease-modifying antirheumatic drug (DMARD) available. Several conventional, biologic, and targeted synthetic DMARDs can serve as alternatives when methotrexate is not tolerated, not effective enough, or medically inappropriate. The choice among them depends on why methotrexate is being replaced, what other health concerns are in play, and how aggressively the disease needs to be controlled.

Why Methotrexate Remains the Starting Point

Methotrexate earned its place at the top of treatment guidelines for good reason. It works as a standalone therapy and pairs well with nearly every other DMARD class, it slows joint damage, and it costs very little compared to newer options.¹ Both the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) continue to recommend it as first-line therapy.² That said, “first-line” does not mean “only line.” Roughly a third of patients either respond inadequately or develop side effects that make staying on it impractical, which is where alternatives come in.

Reasons People Need an Alternative

The most common reason for switching away from methotrexate is side effects. In a large randomized trial, low-dose methotrexate roughly doubled the rate of gastrointestinal problems compared to placebo, and also raised the risk of lung, blood-count, and infection-related events.³ Nausea, mouth sores, and liver-enzyme elevations are the everyday complaints that drive many patients to ask about alternatives long before anything dangerous happens.

Pregnancy planning is another clear-cut reason. Methotrexate is teratogenic and must be stopped one to three months before conception. EULAR guidelines put it in the same category as cyclophosphamide and mycophenolate, requiring effective contraception while on the drug and a washout period before trying to conceive.⁴ For someone who wants to start a family soon, a different DMARD may be needed for months or years.

Liver disease, heavy alcohol use, significant kidney impairment, and certain blood disorders also rule methotrexate out. And some patients simply do not respond well enough, even at the maximum tolerated dose, to keep their disease under control.

Conventional Synthetic DMARDs

These are the oldest and cheapest alternatives. They work differently from methotrexate at the molecular level but occupy the same tier in treatment guidelines. Three stand out as practical substitutes.

Leflunomide

Leflunomide is probably the closest head-to-head substitute for methotrexate. It works by blocking an enzyme that activated immune cells need to multiply. Large trials lasting up to two years found that leflunomide matched methotrexate at reducing tender and swollen joint counts, and it slowed X-ray-visible joint damage at a comparable rate.⁵ In one of those trials, the percentage of patients meeting standard response criteria was statistically equivalent for the two drugs, with a slightly faster initial response on leflunomide.⁶ The side-effect profile is not identical to methotrexate but overlaps: diarrhea, hair thinning, and liver-enzyme bumps are the main concerns. Like methotrexate, leflunomide is also teratogenic, so it does not solve the pregnancy problem.

Sulfasalazine

Sulfasalazine has been around even longer than methotrexate in rheumatology. It is less potent on its own, but it carries a milder side-effect profile and is considered safe enough in pregnancy that many rheumatologists turn to it for women planning to conceive. It is also used in combination strategies: the classic “triple therapy” adds sulfasalazine and hydroxychloroquine to methotrexate (or, for patients who cannot take methotrexate, it forms the backbone of a non-methotrexate combination). Sulfasalazine’s most common complaints are stomach upset and occasional rashes, and it requires periodic blood-count monitoring.

Hydroxychloroquine

Hydroxychloroquine is the mildest DMARD in the conventional arsenal. It works through several pathways, including interference with immune-cell signaling and cytokine production, and has a notably long half-life of around 50 days.⁷ It is widely used for lupus and Sjögren’s syndrome in addition to RA.⁸ On its own, hydroxychloroquine is rarely strong enough to control moderate-to-severe RA. In a study of patients already on other antirheumatic drugs, adding hydroxychloroquine improved functional scores in about 60% of participants, though the difference from controls was not statistically significant by week 24.⁹ Its real value is as a combination partner, not a monotherapy replacement for methotrexate. The well-known safety concern is retinal toxicity with long-term use, which requires regular eye exams.

Combination Therapy Without Methotrexate

When none of the conventional DMARDs is strong enough alone, combining them is a proven strategy. The most studied combination, triple therapy with methotrexate plus sulfasalazine and hydroxychloroquine, performs surprisingly well against biologic drugs in head-to-head trials. A systematic review found that conventional DMARD combinations and TNF-inhibitor-plus-methotrexate regimens both outperformed methotrexate monotherapy by similar margins on standard response measures and joint-damage progression.¹⁰ The trade-off was that conventional combinations led to more treatment withdrawals due to side effects. For patients who genuinely cannot use methotrexate, a sulfasalazine-plus-hydroxychloroquine backbone is an option, though the evidence is thinner since most trials used methotrexate as the anchor.

Biologic DMARDs

Biologics are lab-engineered proteins that target specific molecules in the immune system. They are more expensive than conventional DMARDs and are typically given by injection or infusion. Current guidelines recommend adding a biologic when conventional DMARDs at maximum tolerated doses have not brought the disease to target.¹¹ Several classes exist, and they differ in how they are used when methotrexate is off the table.

TNF Inhibitors

Drugs like adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol block tumor necrosis factor, a key driver of joint inflammation. They are the most widely prescribed biologics in RA. Most of the landmark trials tested them alongside methotrexate, and the combination is more effective than either drug alone. But for patients who cannot take methotrexate, some TNF inhibitors are used as monotherapy or paired with a different conventional DMARD. Registry data from patients with psoriatic arthritis, a related condition, found no significant difference in time to remission between TNF inhibitor monotherapy and TNF inhibitor combined with a conventional DMARD.¹² That said, the RA data tend to favor combination therapy, so going without methotrexate may mean accepting slightly less disease control. Certolizumab is worth a special mention for pregnancy planning: it does not cross the placenta in meaningful amounts and is one of the few biologics considered compatible with pregnancy.

IL-6 Receptor Blockers

Tocilizumab and sarilumab target interleukin-6, another inflammatory signal. These drugs stand out because they work unusually well as monotherapy, making them attractive options when methotrexate is completely off the table. The AMBITION trial compared tocilizumab alone against methotrexate alone in patients who had not previously failed methotrexate: about 70% of the tocilizumab group achieved a standard clinical response, compared to roughly half of the methotrexate group.¹³ In the ADACTA trial, which pitted tocilizumab monotherapy against adalimumab monotherapy, tocilizumab was superior at reducing disease activity.¹⁴ If your rheumatologist suggests an IL-6 blocker specifically because you cannot tolerate methotrexate, this head-to-head monotherapy data is likely the reason.

T-Cell and B-Cell Targeted Agents

Abatacept blocks a co-stimulatory signal that T cells need to become fully activated, and it also affects memory B cells.¹⁵ Rituximab depletes B cells directly and is generally reserved for patients who have failed at least one TNF inhibitor. A meta-analysis found that patients who test positive for rheumatoid factor are significantly more likely to respond to rituximab and tocilizumab, while abatacept response did not appear to depend on rheumatoid factor status.¹⁶ This means blood-test results can help guide which biologic is most likely to work for a given patient.

JAK Inhibitors

Janus kinase (JAK) inhibitors are pills, not injections, and that distinction matters a lot to patients. A survey of 380 people with RA found that route of administration was the single most important treatment attribute, outranking side effects, cost, and even pain reduction. Over half preferred an oral drug.¹⁷ Four JAK inhibitors are approved for RA: tofacitinib, baricitinib, upadacitinib, and filgotinib (the last is not available in the United States).

These drugs are effective. A network meta-analysis comparing all four against methotrexate in treatment-naive patients found that each JAK inhibitor achieved significantly higher remission rates, with upadacitinib showing the strongest numbers.¹⁸ In a head-to-head trial against methotrexate, tofacitinib produced better response rates and less joint damage on X-ray at six months.¹⁹ Another trial found that tofacitinib combined with methotrexate was non-inferior to adalimumab combined with methotrexate, but tofacitinib monotherapy could not be declared non-inferior to either combination regimen.²⁰ So even with JAK inhibitors, pairing them with another DMARD tends to give better results than going solo.

Safety Concerns Specific to JAK Inhibitors

JAK inhibitors came with significant enthusiasm when they launched, but a large post-marketing safety trial dampened it. The ORAL Surveillance study, which enrolled RA patients at high cardiovascular risk, found numerically higher rates of heart attacks, strokes, blood clots, and cancers with tofacitinib compared to TNF inhibitors. This led to a boxed warning from the FDA that was extended across the JAK inhibitor class.²¹ The clinical picture is nuanced: these events were concentrated in patients who already had elevated cardiovascular risk, and registry data from broader populations have not consistently shown the same gap.²² Still, guidelines now suggest that for patients at higher risk of heart disease, blood clots, or malignancy, a biologic should be considered before a JAK inhibitor.²³ For younger, otherwise healthy patients with RA, the absolute risk remains low, and the convenience of a pill is a real advantage.

What Guidelines Say About the Switching Sequence

Both ACR and EULAR guidelines follow a step-up approach. Methotrexate (or another conventional DMARD if methotrexate is contraindicated) comes first. If that does not bring disease activity to target within three to six months, a biologic is added. EULAR’s 2025 update specifies that JAK inhibitors “may be considered” at this step but that cardiovascular and clotting risk factors must be weighed first.¹¹

The ACR’s 2021 guideline conditionally recommends adding a biologic or JAK inhibitor over triple therapy for patients not at target on methotrexate, largely because patients themselves prioritize faster improvement. The guideline panel acknowledged that triple therapy produces equivalent long-term outcomes at much lower cost, and the debate was vigorous before the final vote.² In practice, insurance often requires a trial of methotrexate (or documentation of a clear contraindication) before covering a biologic or JAK inhibitor.

Biosimilars and Cost

Biologic DMARDs can cost tens of thousands of dollars per year, which puts them out of reach for some patients even with insurance. Biosimilars, which are near-identical copies of original biologics manufactured after patent expiration, have begun to change the math. A multicenter study in Spain found that biosimilars had comparable effectiveness to reference biologics in reducing disease activity scores, while providing substantial savings to public health systems.²⁴ Biosimilars now exist for adalimumab, etanercept, infliximab, and rituximab, among others. If cost is a barrier to moving beyond methotrexate, asking specifically about biosimilar options can open doors.

Screening Before Starting a New DMARD

Switching to a biologic or JAK inhibitor is not as simple as swapping one pill for another. These drugs suppress the immune system more selectively than methotrexate, but they still increase infection risk. Before starting, most rheumatologists screen for latent tuberculosis, hepatitis B and C, and sometimes other infections. A clinical audit in a high-burden region found that thorough screening improved treatment outcomes and caught latent infections that could have reactivated on immunosuppressive therapy.²⁵ Vaccinations, particularly for shingles and pneumonia, are also recommended before starting a biologic or JAK inhibitor, since live vaccines become off-limits once you are on these drugs.

Can You Eventually Come Off DMARDs Entirely?

Some patients achieve sustained remission and wonder whether they can taper or stop treatment altogether. The evidence suggests caution. The ARCTIC REWIND trial followed patients in remission on conventional DMARDs over three years. Among those kept on stable doses, 80% remained flare-free. Cutting the dose in half dropped that to 57%, and tapering to complete withdrawal dropped it further to 38%.²⁶ The TARA trial explored a similar idea for patients on both a conventional DMARD and a TNF inhibitor, gradually stepping down each drug over six-month windows.²⁷ The upshot is that drug-free remission is achievable for a meaningful minority of patients, but the majority will flare if treatment is fully withdrawn. Tapering should be done gradually and under close monitoring, not as a unilateral decision.

Predicting Who Will Respond to What

One of the frustrations of RA treatment is trial and error. You might spend months on a drug only to find it does not work for you. Researchers are working on biomarkers that could predict response before you start. One approach identified specific gene-expression patterns in immune cells that predicted whether a patient would respond to methotrexate, achieving around 82% accuracy in a validation set.²⁸ Similar work is underway for biologics: as noted earlier, rheumatoid factor status already helps predict who responds best to rituximab and tocilizumab versus abatacept.¹⁶ None of these tools are in routine clinical use yet, but they represent the direction the field is heading. In a few years, choosing the right DMARD may involve a blood test rather than months of guesswork.